At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 12 enrolled
Drug / intervention
Romidepsin +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study of Venetoclax and Romidepsin With Safety Lead-In for Treatment of Relapsed/Refractory Mature T-Cell Lymphomas
In Brief
A Phase 2 clinical trial evaluating Laboratory Biomarker Analysis, Romidepsin, and 1 other intervention for Anaplastic Large Cell Lymphoma and 2 related conditions. Completed, enrolled 12 participants across 2 sites.
Detailed Summary
This phase II trial studies the side effects and best dose of venetoclax and romidepsin to see how well it works in treating patients with mature T-cell lymphoma that has come back (recurrent) or does not respond to treatment (refractory). Venetoclax and romidepsin may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAnaplastic Large Cell Lymphoma, Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedMay 2018
Enrollment StartAug 2018
Primary CompletionApr 2021
Study CompletionJul 2023
TodayJul 2026
First PostedMay 23, 2018
Enrollment StartAug 21, 2018
Primary CompletionApr 21, 2021
Study CompletionJul 26, 2023
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 8.1 years ago
Interventions
Laboratory Biomarker Analysisother
Correlative studies
Romidepsindrug
Given IV
Venetoclaxdrug
Given PO